LifeMD (LFMD) Expected to Announce Earnings on Wednesday

Key Points

• LifeMD is set to report its Q2 2025 earnings on August 6th, with analysts predicting a loss of ($0.02) per share and revenues of $66.17 million.
• The company recently experienced a 6.2% decline in share price, opening at $10.20, and has faced fluctuations with a 12-month low of $3.99 and a high of $15.84.
• Analysts have raised their price targets for LifeMD, with ranges noted between $14.00 to $18.00, reflecting a generally positive outlook on the stock's performance.

LifeMD (NASDAQ:LFMD - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect LifeMD to post earnings of ($0.02) per share and revenue of $66.17 million for the quarter. LifeMD has set its Q2 2025 guidance at EPS and its FY 2025 guidance at EPS.

LifeMD (NASDAQ:LFMD - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.05. The firm had revenue of $65.70 million during the quarter, compared to the consensus estimate of $62.47 million. On average, analysts expect LifeMD to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

LifeMD Price Performance

LFMD traded down $0.47 during mid-day trading on Friday, hitting $9.94. The stock had a trading volume of 1,102,317 shares, compared to its average volume of 952,678. The stock's fifty day simple moving average is $12.14 and its 200-day simple moving average is $8.34. The firm has a market capitalization of $451.77 million, a price-to-earnings ratio of -29.23 and a beta of 1.72. LifeMD has a 1-year low of $3.99 and a 1-year high of $15.84.

Analyst Ratings Changes

LFMD has been the topic of several recent analyst reports. Wall Street Zen lowered LifeMD from a "buy" rating to a "hold" rating in a report on Saturday. BTIG Research lifted their price objective on LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a report on Wednesday, June 18th. HC Wainwright reissued a "buy" rating and set a $14.00 target price on shares of LifeMD in a research note on Wednesday, April 30th. KeyCorp lifted their price target on shares of LifeMD from $12.00 to $14.00 and gave the company an "overweight" rating in a research note on Monday, July 14th. Finally, Lake Street Capital raised their price objective on shares of LifeMD from $12.00 to $18.00 and gave the stock a "buy" rating in a report on Thursday, July 10th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $13.86.

Insider Buying and Selling

In related news, CEO Justin Schreiber sold 25,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $13.38, for a total transaction of $334,500.00. Following the completion of the transaction, the chief executive officer directly owned 2,500,721 shares of the company's stock, valued at approximately $33,459,646.98. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Marc David Benathen sold 75,000 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $13.09, for a total value of $981,750.00. Following the transaction, the chief financial officer directly owned 389,554 shares in the company, valued at $5,099,261.86. This trade represents a 16.14% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 275,000 shares of company stock worth $3,564,550 over the last 90 days. 18.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in LifeMD stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 4.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 49,647 shares of the company's stock after buying an additional 2,235 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned 0.11% of LifeMD worth $270,000 at the end of the most recent quarter. Institutional investors own 35.52% of the company's stock.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.